Other OTC - Delayed Quote USD

Minerva Surgical, Inc. (UTRS)

0.0010 0.0000 (0.00%)
At close: May 2 at 1:18 PM EDT
Loading Chart for UTRS
DELL
  • Previous Close 0.0010
  • Open 0.0010
  • Bid --
  • Ask --
  • Day's Range 0.0010 - 0.0010
  • 52 Week Range 0.0010 - 14.0000
  • Volume 26,196
  • Avg. Volume 2,125
  • Market Cap (intraday) 8,879
  • Beta (5Y Monthly) 1.14
  • PE Ratio (TTM) --
  • EPS (TTM) -7.6100
  • Earnings Date Jul 31, 2024 - Aug 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

minervasurgical.com

174

Full Time Employees

December 31

Fiscal Year Ends

Recent News: UTRS

Performance Overview: UTRS

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

UTRS
99.91%
S&P 500
11.18%

1-Year Return

UTRS
99.98%
S&P 500
29.04%

3-Year Return

UTRS
100.00%
S&P 500
16.69%

5-Year Return

UTRS
100.00%
S&P 500
16.69%

Compare To: UTRS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: UTRS

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    8.88k

  • Enterprise Value

    32.43M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.00

  • Price/Book (mrq)

    0.00

  • Enterprise Value/Revenue

    0.63

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -64.71%

  • Return on Assets (ttm)

    -27.34%

  • Return on Equity (ttm)

    -160.07%

  • Revenue (ttm)

    51.69M

  • Net Income Avi to Common (ttm)

    -33.45M

  • Diluted EPS (ttm)

    -7.6100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.12M

  • Total Debt/Equity (mrq)

    215.01%

  • Levered Free Cash Flow (ttm)

    -18.49M

Research Analysis: UTRS

Company Insights: UTRS

Research Reports: UTRS

People Also Watch